[S29] The consideration of the ideal form of PMDA's review reports as drug information —from the perspectives of the regulatory authorities, medical institutions, and industries—

1:25 PM - 1:40 PM JST(4:25 AM - 4:40 AM UTC)

[S29-2] 審査報告書の役割

○Takashi Yasukawa¹ (1. Pharmaceuticals and Medical Devices Agency)

Password required to view

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.